A double-blind, multicenter, randomized, placebo-controlled study of safety and efficacy of trospium chloride 60 mg modified release capsules versus placebo, once daily, for 12 weeks followed by a 9-month, open label treatment phase in patients with overactive bladder

Trial Profile

A double-blind, multicenter, randomized, placebo-controlled study of safety and efficacy of trospium chloride 60 mg modified release capsules versus placebo, once daily, for 12 weeks followed by a 9-month, open label treatment phase in patients with overactive bladder

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2011

At a glance

  • Drugs Trospium chloride (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Endo Pharmaceuticals Solutions
  • Most Recent Events

    • 01 Mar 2008 Results have been published.
    • 05 Apr 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top